[HTML][HTML] Physiologically based pharmacokinetic (PBPK) modeling to predict PET image quality of three generations EGFR TKI in advanced-stage NSCLC patients
IH Bartelink, EA van de Stadt, AF Leeuwerik… - Pharmaceuticals, 2022 - mdpi.com
Introduction: Epidermal growth factor receptor (EGFR) mutated NSCLC is best treated using
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
an EGFR tyrosine kinase inhibitor (TKI). The presence and accessibility of EGFR …
[HTML][HTML] Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using …
EA van de Stadt, M Yaqub, RC Schuit, IH Bartelink… - Diagnostics, 2022 - mdpi.com
Background: Patients with non-small cell lung cancer (NSCLC) driven by activating
epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting …
epidermal growth factor receptor (EGFR) mutations are best treated with therapies targeting …
[HTML][HTML] A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing …
P Slobbe, AD Windhorst, M Stigter-van Walsum… - EJNMMI research, 2015 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) have experienced a tremendous
boost in the last decade, where more than 15 small molecule TKIs have been approved by …
boost in the last decade, where more than 15 small molecule TKIs have been approved by …
[HTML][HTML] Evaluation of quantitative modeling methods in whole-body, dynamic [11C]-erlotinib PET
Background:[11 C]-Erlotinib is a radiolabeled analogue of a tyrosine kinase inhibitor used to
treat non-small cell lung cancer (NSCLC) which expresses specific kinase domain mutations …
treat non-small cell lung cancer (NSCLC) which expresses specific kinase domain mutations …
Predictive efficacy of 11C‐PD153035 PET imaging for EGFR–tyrosine kinase inhibitor sensitivity in non‐small cell lung cancer patients
D Dai, XF Li, J Wang, JJ Liu, YJ Zhu… - … Journal of Cancer, 2016 - Wiley Online Library
To determine the correlation of 11C‐PD153035 uptake with epidermal growth factor
receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sensitivity and phosphorylated EGFR …
receptor‐tyrosine kinase inhibitor (EGFR‐TKI) sensitivity and phosphorylated EGFR …
[HTML][HTML] PET/CT radiomic features: a potential biomarker for EGFR mutation status and survival outcome prediction in NSCLC patients treated with TKIs
L Yang, P Xu, M Li, M Wang, M Peng, Y Zhang… - Frontiers in …, 2022 - frontiersin.org
Backgrounds Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in
treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this …
treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this …
[HTML][HTML] Effects of erlotinib therapy on [11C]erlotinib uptake in EGFR mutated, advanced NSCLC
Background In non-small cell lung cancer (NSCLC) patients off erlotinib therapy, positron
emission tomography (PET) using [11 C] erlotinib distinguished epidermal growth factor …
emission tomography (PET) using [11 C] erlotinib distinguished epidermal growth factor …
[HTML][HTML] Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
EA van de Stadt, M Yaqub, AA Lammertsma, AJ Poot… - EJNMMI research, 2020 - Springer
Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) …
[HTML][HTML] The development of positron emission tomography tracers for in vivo targeting the kinase domain of the epidermal growth factor receptor
A Högnäsbacka, AJ Poot, DJ Vugts… - Pharmaceuticals, 2022 - mdpi.com
Multiple small molecule PET tracers have been developed for the imaging of the epidermal
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …
growth factor receptor (EGFR). These tracers target the tyrosine kinase (TK) domain of the …
Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors
H Su, Y Seimbille, GZ Ferl, C Bodenstein… - European journal of …, 2008 - Springer
Purpose Gefitinib, an inhibitor of the epidermal growth factor receptor–tyrosine kinase
(EGFR-TK), has shown potent effects in a subset of patients carrying specific EGFR-TK …
(EGFR-TK), has shown potent effects in a subset of patients carrying specific EGFR-TK …